This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Friday, March 8, 2013
Dr Matthew Foxton, hepatologist, joins HepatitisCNews.com
Dr Matthew Foxton, hepatologist, joins HepatitisCNews.com
Dr Matthew Foxton, consultant hepatologist at Chelsea & Westminster Hospital and King’s College Hospital in London, has joined the hepatitisCnews.com team.
Dr Matthew Foxton, consultant hepatologist at Chelsea & Westminster Hospital and King’s College Hospital in London, has joined the hepatitisCnews.com team.
Dr Foxton will advise the team as well as answering reader queries on all aspects of living well with hepatitis C. A selection of responses will be published on the site each week.
Developed to deliver accessible information on hepatitis C, an infectious liver disease that affects around 150 million people worldwide, hepatitisCnews.com was launched in late 2012. The site features daily news updates on hepatitis C and tips on living well with the hep C virus, as well as details of resources and support groups worldwide.
Often referred to as a silent disease, as in most cases it does not result in any symptoms, hepatitis C is most commonly transmitted through contact with an infected person’s blood. The hepatitis C virus can cause serious damage to the liver and, if left untreated, can result in scarring of the liver, liver disease or even death.
Dr Matthew Foxton qualified from St George’s Hospital Medical School in 1995. He undertook specialist training in gastroenterology in the South East London region and completed his training in 2007 having gained sub-specialty accreditation in hepatology. He was awarded an MD from the University of London in 2009 following the submission of his thesis on hepatitis C recurrence after liver transplantation. He was appointed as a consultant in gastroenterology at Queen Elizabeth Hospital, Woolwich in 2007 where he set up a Fibroscan service (one of the first NHS funded Fibroscan services in the country). He was appointed as consultant hepatologist at Chelsea and Westminster Hospital and King’s College Hospital in 2010.
For further information, visit http://www.hepatitiscnews.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment